Evidence map›Paper›PMID 42491058›Full record

ReviewGenes & diseases2026

The role of FGF19-FGFR4 signaling pathway in liver health and disease: Guardian or destroyer.

Zhangfan Wu, Yijun Wang, Jiaqian Zhang, Siwen Li, Junjie Wen, Dian Hu, Junqing Jiang, Zerui Zhang, Xiangyuan Luo, Limin Xia

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhangfan WuDepartment of Gastroenterology, Institute of Liver and Gastrointestinal Diseases, Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
Yijun WangDepartment of Gastroenterology, Institute of Liver and Gastrointestinal Diseases, Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
Jiaqian ZhangDepartment of Gastroenterology, Institute of Liver and Gastrointestinal Diseases, Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
Siwen LiDepartment of Gastroenterology, Institute of Liver and Gastrointestinal Diseases, Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
Junjie WenDepartment of Gastroenterology, Institute of Liver and Gastrointestinal Diseases, Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
Dian HuDepartment of Gastroenterology, Institute of Liver and Gastrointestinal Diseases, Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
Junqing JiangDepartment of Gastroenterology, Institute of Liver and Gastrointestinal Diseases, Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
Zerui ZhangDepartment of Gastroenterology, Institute of Liver and Gastrointestinal Diseases, Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
Xiangyuan LuoDepartment of Gastroenterology, Institute of Liver and Gastrointestinal Diseases, Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
Limin XiaDepartment of Gastroenterology, Institute of Liver and Gastrointestinal Diseases, Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The fibroblast growth factor (FGF) 15/19-FGF receptor (FGFR) 4 signaling pathway is a crucial endocrine regulatory pathway within the FGF family. The FGF15/19-FGFR4 signaling pathway plays multiple key roles in the liver, involving core physiological processes such as metabolic regulation, bile acid homeostasis maintenance, and hepatocyte proliferation and repair, and is also closely related to the pathogenesis of various liver diseases. At present, targeted therapeutic strategies for the FGF19-FGFR4 signaling axis have shown significant therapeutic potential. Agonists that simulate the physiological functions of FGF19 have been proven to effectively regulate bile acid and lipid metabolism in metabolic diseases and improve liver steatosis and fibrosis. Meanwhile, drugs that selectively inhibit FGFR4 have also demonstrated positive anti-tumor activity in specific tumor types driven by FGF19 overexpression. Given the crucial role of FGF19-FGFR4, clarifying the key mechanisms of this pathway in both physiology and pathology, as well as summarizing targeted therapy, is of vital importance. This review highlights the key role of FGF15/19-FGFR4 signaling in regulating liver physiological functions and reveals how its abnormal expression contributes to the occurrence of benign and malignant liver diseases. In addition, this review points out the potential of FGF15/19-FGFR4 signaling as a biomarker in different liver diseases and briefly discusses the existing treatment strategies for this signaling pathway.

Indexed as

Fibroblast growth factor 19Fibroblast growth factor receptor 4Hepatocellular carcinomaLiver diseaseMetabolic dysfunction-associated steatotic liver disease

Identifiers

PMID42491058
PMCPMC13375949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.